A phase II study with vinorelbine, gemcitabine and cisplatin in the treatment of patients with stage IIIb-IV non-small cell lung cancer (NSCLC).

@article{Ginopoulos1999API,
  title={A phase II study with vinorelbine, gemcitabine and cisplatin in the treatment of patients with stage IIIb-IV non-small cell lung cancer (NSCLC).},
  author={Panagiotis Ginopoulos and Nicholas S. Mastronikolis and John N Giannios and Afroditi Karana and V Siabi and F Karvelas and S Rathossis and Nikolaos V. Apostolopoulos and Anna Mastorakou},
  journal={Lung cancer},
  year={1999},
  volume={23 1},
  pages={31-7}
}
In our phase II study an acceptable and effective agent like cisplatin was used in combination with vinorelbine and gemcitabine in patients with non-small cell lung cancer (NSCLC). These two new cytostatic drugs have demonstrated, when used as a single-agent treatment, effective response rates (vinorelbine) and minimum toxicity (gemcitabine). The following schedule was used: (i) vinorelbine 25 mg/m2 on days 1 and 8; (ii) gemcitabine 1000 mg/m2 on days 1 and 8; and (iii) cisplatin 75 mg/m2 on… CONTINUE READING